Feeds:
Posts
Comments

Posts Tagged ‘new alzheimer's drug’

alz

 The San Diego Tribune (8/10, LaFee http://tinyurl.com/alzheimers-gene-therapy) reports that “researchers at the University of California-San Diego” are “seeking qualified study volunteers” in preparation for launching “the second-phase clinical trial (http://tinyurl.com/NGF-alzheimers-phaseII-study) of a promising gene therapy for Alzheimer’s disease.” In previous “animal and human safety trials, a gene therapy” medication “called CERE-110 was injected into patients’ brains, initially via modified skin cells, later using a harmless viral carrier. CERE-110 carries a gene that promotes long-term production of nerve growth factor (NGF), a natural molecule that helps brain cells live and function longer.” The new “phase 2 trial will be conducted at 12 US sites” and will “involve…volunteers between the ages of 50 and 80 with mild to moderate Alzheimer’s symptoms.” During the “randomized,” blind study, “half of the participants” will receive “CERE-110, and the other half” will get “a placebo.” After completion of the study “in 2012…participants in the placebo group will be eligible to be treated with CERE-110,” should the phase II results be promising.

Read Full Post »

The AP (5/21) reported, “Eli Lilly & Co. said Thursday it will start late-stage clinical testing of an Alzheimer’s disease” medication candidate, solanezumab, “with enrollment of patients scheduled to begin this month.” The medication “candidate is intended to prevent the progression of mild to moderate Alzheimer’s disease,” and Lilly plans “two separate late-stage trials, which will involve a total of 2,000 patients age 55 and older.” The trials will involve patients taking “a 400 mg infusion of solanezumab or a placebo once every four weeks” for 18 months, and will “test whether solanezumab is better than the placebo at slowing the mental and functional decline of Alzheimer’s patients.”

The Indianapolis Star (5/21, Spalding) added that patients in the “separate but identical” Expedition trials will be “from 16 countries, including the US.” The company “also is in the process of testing out a different type of Alzheimer’s treatment, also geared to help those with the disease, which is known to cause dementia.” Eric Siemers, MD, medical director for Lilly’s Alzheimer’s disease research, said, “Biomarker results from a phase II solanezumab trial give us hope that Lilly is on a path toward a treatment that may slow the rate of progression of Alzheimer’s disease.”

       

According to Reuters (5/22), both of the medicines that Lilly is testing target amyloid beta protein fragments in the brain that are believed to be linked to Alzheimer’s.

Read Full Post »